Literature DB >> 23380371

Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.

Melanie J Grubisha1, Donald B DeFranco.   

Abstract

Androgen receptor (AR) signaling is essential for the initial development and progression of prostate cancer (PCa) as well as the growth and survival of castration-resistant tumors. However, AR action may be opposed by estrogen receptor beta (ERß) that responds to androgen metabolites produced in the prostate. The balance between the activity of these two receptors is not only influenced by the steroidogenic capacity of the prostatic microenvironment but also by its redox status and local paracrine signals such as transforming growth factor-beta (TGF-ß). In this review, we highlight the studies that revealed select roles for AR and ERß in distinct compartments of the prostate cancer microenvironment. We also discuss new work that identified stromal-epithelial crosstalk through TGF-ß1 signaling that drives the production of reactive oxygen species in stromal cells thereby selectively limiting the anti-tumor activity of ERß in cancer cells. Therefore, any new therapeutic approaches that seek to limit AR but enhance ERß activity in PCa, must take into account potential adaptive changes in the tumor microenvironment that utilize paracrine signals and altered redox balance to divert local androgen metabolites towards AR at the expense of ERß.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380371      PMCID: PMC3644803          DOI: 10.1016/j.steroids.2013.01.005

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  46 in total

Review 1.  The role of hormonal treatment in prostate cancer.

Authors:  Stephan H Flüchter; Ralf Weiser; Christoph Gamper
Journal:  Recent Results Cancer Res       Date:  2007

2.  Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life.

Authors:  Joseph John Bianco; Stephen John McPherson; Hong Wang; Gail S Prins; Gail Petuna Risbridger
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 3.  Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling.

Authors:  Gail P Risbridger; Stuart J Ellem; Stephen J McPherson
Journal:  J Mol Endocrinol       Date:  2007-09       Impact factor: 5.098

Review 4.  Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent.

Authors:  R S Swerdloff; C Wang
Journal:  Baillieres Clin Endocrinol Metab       Date:  1998-10

5.  Reactivity of zinc finger cysteines: chemical modifications within labile zinc fingers in estrogen receptor.

Authors:  Christian Atsriku; Gary K Scott; Christopher C Benz; Michael A Baldwin
Journal:  J Am Soc Mass Spectrom       Date:  2005-10-24       Impact factor: 3.109

6.  Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.

Authors:  Jong Y Park; Jean-Paul Tanner; Thomas A Sellers; Yifan Huang; Colleen K Stevens; Nicole Dossett; Ravi A Shankar; Babu Zachariah; Randy Heysek; Julio Pow-Sang
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 7.  Expression of steroidogenic enzymes and sex-steroid receptors in human prostate.

Authors:  Georges Pelletier
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

8.  Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.

Authors:  Binod Kumar; Sweaty Koul; Lakshmipathi Khandrika; Randall B Meacham; Hari K Koul
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

Review 9.  The role of epithelial-mesenchymal transition in cancer pathology.

Authors:  Marcello Guarino; Barbara Rubino; Gianmario Ballabio
Journal:  Pathology       Date:  2007-06       Impact factor: 5.306

View more
  9 in total

Review 1.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 2.  Environmental immune disruptors, inflammation and cancer risk.

Authors:  Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 3.  Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death.

Authors:  Kannan Badri Narayanan; Manaf Ali; Barry J Barclay; Qiang Shawn Cheng; Leandro D'Abronzo; Rita Dornetshuber-Fleiss; Paramita M Ghosh; Michael J Gonzalez Guzman; Tae-Jin Lee; Po Sing Leung; Lin Li; Suidjit Luanpitpong; Edward Ratovitski; Yon Rojanasakul; Maria Fiammetta Romano; Simona Romano; Ranjeet K Sinha; Clement Yedjou; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Elizabeth P Ryan; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Hosni K Salem; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Seo Yun Kim; William H Bisson; Leroy Lowe; Hyun Ho Park
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 4.  Metabolic syndrome in prostate cancer: impact on risk and outcomes.

Authors:  Fatima H Karzai; Ravi A Madan; William L Dahut
Journal:  Future Oncol       Date:  2016-04-12       Impact factor: 3.404

Review 5.  The role of estrogen receptor β in prostate cancer.

Authors:  Paraskevi Christoforou; Panagiotis F Christopoulos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-10-02       Impact factor: 6.354

6.  Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.

Authors:  Maria Angeles Lillo Osuna; Jesus Garcia-Lopez; Ikbale El Ayachi; Iram Fatima; Aysha B Khalid; Jerusha Kumpati; Alexandria V Slayden; Tiffany N Seagroves; Gustavo A Miranda-Carboni; Susan A Krum
Journal:  Cancer Res       Date:  2018-12-28       Impact factor: 12.701

7.  Estrogen Receptors Promote Migration, Invasion and Colony Formation of the Androgen-Independent Prostate Cancer Cells PC-3 Through β-Catenin Pathway.

Authors:  Ana Paola G Lombardi; Carolina M Vicente; Catarina S Porto
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-09       Impact factor: 5.555

Review 8.  The Regulation of Steroid Action by Sulfation and Desulfation.

Authors:  Jonathan W Mueller; Lorna C Gilligan; Jan Idkowiak; Wiebke Arlt; Paul A Foster
Journal:  Endocr Rev       Date:  2015-07-27       Impact factor: 19.871

Review 9.  Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer.

Authors:  Erika Di Zazzo; Giovanni Galasso; Pia Giovannelli; Marzia Di Donato; Antonio Bilancio; Bruno Perillo; Antonio A Sinisi; Antimo Migliaccio; Gabriella Castoria
Journal:  Cancers (Basel)       Date:  2019-09-23       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.